PIVOTAL PHASE II/III OF MURINE RADIOIMMUNOTHERAPY FOR LYMPHOMAS

鼠淋巴瘤放射免疫治疗的关键 II/III 期

• 批准号: 6115083
• 负责人: Susan J. Knox
• 金额: $ 4.03万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115083
• 关键词: B cell lymphoma; CD antigens; antibody; antitumor antibody; clinical research; combination cancer therapy; cytotoxicity; drug administration rate /duration; drug screening /evaluation; human subject; human therapy evaluation; imaging /visualization /scanning; iodine; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; radionuclide imaging /scanning; radionuclides; radiotracer

This is a continuation of studies designed to evaluate the efficacy and safety of 131 Iodine-labeled anti-CD20 (131 I-anti-B1) as therapy for low-grade and transformed B-cell lymphoma. Patients will receive an imaging and therapeutic dose of radiolabeled antibody and will be followed for response, duration and toxicity. Patients will receive the imaging dose as outpatients, and the therapeutic dose as inpatients for 3 to 5 days.

这是一项旨在评估疗效和 131I标记抗CD20(131I-抗-B1)治疗肺癌的安全性 低度恶性转化的B细胞淋巴瘤。患者将收到一份 放射性标记抗体的成像和治疗剂量 随后观察其反应、持续时间和毒性。患者将收到 影像剂量为门诊病人，治疗剂量为住院病人。 3至5天。